Impact of Huisheng Oral Solution Combined with Immune Checkpoint Inhibitors and Chemotherapy in Patients with Stage III-IV Non-Small Cell Lung Cancer: A Retrospective Analysis.

ABSTRACT: Background: To evaluate the impact of Huisheng Oral Solution (HSOS) in conjunction with immune checkpoint inhibitors (ICIs) and chemotherapy on patients with stage III-IV non-small cell lung cancer (NSCLC). Methods: This retrospective study included patients with stage III-IV NSCLC who were treated at Sichuan Provincial People's Hospital from May 2018 to June 2021. Patients were categorized into two groups: the ICIs & Chemo Group and the ICIs & Chemo & HSOS Group, based on the therapies administered. The disease control rate (DCR), objective response rate (ORR), progression-free survival (PFS), overall survival (OS), and immune-related adverse events (irAEs) were assessed. Results: A total of 185 patients were included, with 109 patients in ICIs & Chemo & HSOS Group. T

SUBMITTER: Bai Y 

PROVIDER: S-EPMC12435248 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature